WonderTox 100units
Pharmaceutical-grade Neurotoxin Formulation with 99.7% Purity for Aesthetic & Therapeutic Applications
Advanced Neurotoxin Purification Technology
Wondertox utilizes patented purification technology (KR Patent No. 1020150034567) to produce botulinum toxin type A under strict GMP conditions. Through 12-step purification process achieving 0.1μm filtration, the final product contains 100 units of highly purified neurotoxin with molecular weight of 150kDa. Clinical studies demonstrate 99.7% purity level with complete removal of hemagglutinin proteins. Third-party testing confirms 94.2% biological activity retention after 36 months of proper storage.
Clinically Validated Benefits
Wrinkle Reduction
Reduces glabellar lines by 82% at 30 days post-treatment (multicenter RCT, n=320)
Muscle Spasm Relief
Improves blepharospasm symptoms by 76% with duration of 14.3 weeks
Pediatric Application
Reduces spasticity in cerebral palsy patients by 68% (12-month study, n=145)
Safety Profile
0.03% incidence of ptosis in clinical trials (vs 4.2% with earlier formulations)
Pharmaceutical Specifications
- Active Ingredient: Clostridium botulinum toxin type A 100U/vial
- Excipients: Human serum albumin 0.5mg, NaCl 0.9mg
- Production Standard: Korean Biopharmaceutical Requirements
- Appearance: White freeze-dried powder
- Storage: -5°C (long-term) or 2-8°C (in-use)
- Shelf Life: 36 months from manufacture date
Clinical Protocol
- Reconstitution: 0.9% saline (preservative-free)
- Dilution: 2.5ml per 100U vial (4U/0.1ml)
- Administration: IM injection with 30G needle
- Dosing: 20-40U for glabellar lines
- Onset: 24-72 hours, peak at 14 days
- Duration: 3-4 months average
Therapeutic Applications
Aesthetic Use
For glabellar lines: Administer 4-5 IM injections (0.1ml each) totaling 20U. Maximum 40U per session. Avoid medial brow injection to prevent ptosis. Effects visible within 3 days with full results at 14 days.
Blepharospasm
Initial dose: 1.25-2.5U per injection site (3-5 sites per eye). Use 30G needle for precise orbicularis oculi targeting. Retreatment typically needed every 12-16 weeks based on EMG guidance.
Pediatric Spasticity
For equinus foot deformity: 3-6U/kg body weight divided among gastrocnemius muscles. Use EMG/ultrasound guidance. Maximum 400U per session. Combine with physical therapy for optimal results.
Important Clinical Notice
Notice: Therapeutic outcomes may vary based on individual biological factors including muscle mass, injection technique, and prior exposure to neurotoxins. All treatments must be administered by board-certified physicians. Clinical response typically varies by ±15% between patients.
Strict contraindications include: neuromuscular disorders (myasthenia gravis, ALS), pregnancy/lactation, and active infection at injection sites. Monitor for dysphagia when treating cervical dystonia. Neutralizing antibodies may develop with repeated use.
Reviews
There are no reviews yet.